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Abstract
Purpose To assess the efficacy and safety of panzyga® (intra-
venous immunoglobulin 10%) in preventing serious bacterial
infections (SBIs) in patients with primary immunodeficiency
diseases (PIDs), a prospective, open-label, multicenter, phase
3 study and an open-label extension study were undertaken.
Methods Initially, the study drug (infusion rate ≤0.08 mL/kg/
min) was administered at intervals of 3 or 4 weeks for
12 months, followed by 3 months of panzyga® at infusion
rates increasing from 0.08 to 0.14 mL/kg/min. The primary
endpoint in the main study was the rate of SBIs per patient-
year on treatment. Secondary outcomes included non-serious
infections, work/school absence, episodes of fever, quality of
life, and adverse events (AEs).
Results The main study enrolled 51 patients (35% female,
mean age 26.8 years), with 21 participating in the extension
study. The rate of SBIs per patient-year was 0.08 in the total
population; there were four SBIs in the 4-weekly treatment
group (2/30 patients) and none in the 3-weekly group
(n = 21). Compared with 4-weekly treatment, 3-weekly treat-
ment was associated with a higher rate of upper respiratory
tract infections (RTIs), ear infections, and work/school ab-
sences, but a lower rate of lower RTIs and fever. Treatment
was generally well tolerated; no AE led to treatment with-
drawal or death.
Conclusions Overall, the use of panzyga® in patients with
antibody-deficient PID was associated with a low rate of
AEs and was effective in preventing SBIs, exceeding US
FDA and European Medicines Agency recommendations for
efficacy.
Keywords Primary immunodeficiency diseases . intravenous
immunoglobulin . panzyga® . serious bacterial infections
Introduction
Primary immunodeficiency diseases (PIDs) comprise a het-
erogeneous group of disorders that have intrinsic defects in-
volving the development and function of the immune system
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[1]. To date, >300 molecularly defined disorders have been
identified with new PIDs still being added and classification
ongoing [2]. Children and adults with PID and predominant
antibody deficiency have an increased risk of severe bacterial,
viral, and fungal infections, and present with infections that
typically involve the upper and lower respiratory tracts, the
gastrointestinal system, skin, and other organs [3].
Furthermore, patients with PID are at greater risk of develop-
ing malignancies [4] and autoimmune disorders [5]. Because
most of these antibody deficiencies cannot be cured, affected
patients require lifelong infusions with intravenous or subcu-
taneous immunoglobulin G (IVIG or SCIG) [6]. Replacement
therapy with IVIG or SCIG provides patients with predomi-
nant antibody deficiency with specific antibodies, thus
preventing serious bacterial and viral infections and reducing
the number and duration of hospitalizations, as well as the loss
of school/work days [6, 7].
This report describes the results of a phase 3 study of 12-
month duration and its 3-month extension; the main study
objective was to assess efficacy and safety of two treatment
schedules of 10% IVIG (panzyga®; Octapharma AG, Lachen,
Switzerland) in preventing serious bacterial infections (SBIs),
while the extension study provided data on the tolerability of
panzyga® administered at high infusion rates.
Methods
The protocols for both studies were reviewed and approved by
each study site’s Independent Ethics Committee or
Institutional Review Board before the study commenced.
The studies were conducted in accordance with the ethical
principles of the Declaration of Helsinki and the
International Conference on Harmonization guideline E6:
Good Clinical Practice. Adult patients provided written in-
formed consent; for minors, both written informed assent (as
applicable for the study site) and consent from the patient and
the patient’s parent/legal guardian, respectively, were
required.
Study Design
Main Study
This prospective, open-label, non-controlled, non-random-
ized, multicenter phase 3 study examined two panzyga® in-
fusion regimens administered every 3 or 4 weeks for
12 months in patients with PID from the USA and Europe
(ClinicalTrials.gov record NCT01012323).
Inclusion criteria were age 2–75 years, confirmed diagnosis
of common variable immunodeficiency disorders (CVIDs) or
X-linked agammaglobulinemia (XLA), previous treatment
with a commercial IVIG at a dose of 200–800 mg/kg body
weight every 21–28 days for at least six infusion intervals, and
evidence of an IgG trough level of ≥550mg/dL at the previous
two infusions before enrolment. Female patients of childbear-
ing potential had to have a negative pregnancy test and use a
reliable contraceptive method during the study. A minimum
weight requirement was based on the blood test volumes
needed for the study.
The main exclusion criteria were (1) requirement for rou-
tine premedication for IVIG infusion, (2) severe impairment
of liver function, (3) abnormal renal function, (4) congestive
heart failure or uncontrolled arterial hypertension, (5) a posi-
tive screening test for HIV and/or hepatitis B or C infection,
(6) treatment with immunosuppressive or immunomodulatory
drugs, and (7) pregnant or nursing women.
This study was designed in accordance with the US Food
and Drug Administration (FDA) and European Medicines
Agency (EMA) guidelines on the clinical investigation of hu-
man IVIG [8, 9].
Extension Study
Patients in the USA who had completed the main study and
were 6 years or older were eligible to enroll in the extension
study (ClinicalTrials.gov record NCT01313507). A further
inclusion criterion was administration of the maximum
infusion rate (0.08 mL/kg/min; 480 mg/kg/h) for the last
three infusions of the main study, without need for
premedication. Exclusion criteria were any condition or
circumstance that would result in exclusion from the main
study, administration of any immunoglobulin apart from
panzyga® between the conclusion of the main study and
start of the extension study, and any deviation in the
patient’s treatment interval of >7 days between the last
infusion in the main study and the first infusion in the
extension study.
Study Medication
Panzyga® is a ready-to-use, sterile, glycine-stabilized 10%
liquid preparation of polyvalent human immunoglobulin G
(IgG) for intravenous administration with physiologic osmo-
lality (240–310 mosmol/kg). Virus safety is achieved through
a combination of various process steps, including S/D treat-
ment, ion-exchange chromatography, and nanofiltration
(20 nm).
Main Study
Each enrolled patient received 200–800mg/kg bodyweight of
study drug every 21 (±3) or 28 (±3) days for 12months, unless
medical conditions or other circumstances resulted in the pa-
tient’s withdrawal from the study. Individual treatment doses
and intervals were dependent upon the patient’s previous
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IVIG dose and dosing frequency before entry into the study.
Patients received treatment using an infusion pump at the fol-
lowing rates: 0.01mL/kg/min for the first 30 min, followed by
0.02 mL/kg/min for the second 30 min; infusion rates were
then increased every 30 min using predefined patterns with
maximum rates of 0.04mL/kg/min (first and second infusion),
0.06 mL/kg/min (third and fourth infusion), 0.07 mL/kg/min
(fifth and sixth infusion), and 0.08 mL/kg/min (all subsequent
infusions). Rate increases were only made if the lower infu-
sion rate was tolerated. Patients receiving treatment every
3 weeks had a total of 17 infusions, and those receiving treat-
ment every 4 weeks had a total of 13 infusions.
Extension Study
The dose and infusion schedule remained unchanged from the
main study. Patients received panzyga® using an infusion
pump at the following rates: 0.01 mL/kg/min for the first
30 min, followed by 0.03 mL/kg/min for 15 min; infusion
rates were then increased every 15 min using predefined pat-
terns with maximum rates of 0.10 mL/kg/min (first infusion),
0.12 mL/kg/min (second infusion), and 0.14 mL/kg/min (all
subsequent infusions). Rate increases were only made if the
prior infusion rate was tolerated. Patients receiving treatment
every 3 weeks had a total of five infusions, and those receiving
treatment every 4 weeks had a total of four infusions.
Treatment Outcomes
Main Study
The primary efficacy endpoint was the rate of SBIs (defined as
bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic
arthritis, bacterial pneumonia, and visceral abscess) per
patient-year on treatment. Secondary endpoints included the
number of episodes per patient-year of other infections; the
type, severity, and time to resolution of other infections; num-
ber of days of use of antibiotics per patient-year on treatment
and type and dose; number of days of absence from school or
work per patient-year on treatment; hospitalizations due to
infection and number of days of hospitalization per patient-
year on treatment; reason for hospitalization; and number of
episodes of fever per patient-year on treatment. These data
were collected from patient diaries which were checked by
the investigator at each visit.
Safety assessments included type and frequency of adverse
events (AEs), laboratory parameters (hematology, biochemis-
try, direct Coombs test, urinalysis, and viral markers), vital
signs, and physical examination. The severity of AEs was
described as mild (no significant discomfort to patient or
change in routine activities), moderate (limitation in activity
with possible need for some assistance; no or minimal medical
intervention/therapy required), or severe (marked limitation in
activity with required assistance; medical intervention/therapy
required). AEs were identified as serious (SAEs) if they re-
sulted in death or persistent or significant disability/incapacity,
were life-threatening, required hospitalization or prolongation
of existing hospitalization, or other important medical event.
Extension Study
The primary endpoint was occurrence of AEs causally and/or
temporally related to panzyga® given at infusion rates of up to
0.14 mL/kg/min. The safety parameters assessed were the
same as those in the main study.
Statistical Analysis
The statistical software package used in both studies was SAS,
version 9.1 or higher.
Main Study
The full analysis set (FAS) included all patients who received
≥1 complete treatment and had available data on infections
from ≥1 post-treatment diary. The per-protocol (PP) set
consisted of those patients in the FAS with no major protocol
violations. The safety set included all patients who had re-
ceived at least one infusion. The rate of SBI/year for each
patient was presented as point estimates of the rate along with
a 99% confidence interval (CI) and was calculated as r = (total
number of SBIs) / (patient-years on panzyga® treatment). The
null hypothesis was to be rejected if the upper one-sided con-
fidence limit for SBI rate per patient-year was less than 1.0,
tested at the 1% significance level. The planned sample size
was 50 patients, based on an SBI frequency of <0.5/year in
patients receiving regular IVIG [8], and accounting for an
overall dropout rate of 15%.
Extension Study
The planned number of patients for the extension studywas 20–
35, based on the number of patients enrolled in the main study
from US study sites who completed the study at the maximum
infusion rate and without the need for premedication and did
not meet the exclusion criteria for the extension study.
Results
Patient Characteristics
Main Study
In total, 51 patients (13 children [≥2 to <12 years], 12 adoles-
cents [≥12 to <16], and 26 adults [≥16 to ≤75]) were enrolled
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from 11 study centers, seven in the USA and four in Europe.
The patient disposition through the study is outlined in Fig. 1.
One patient with bronchiectasis on a 4-week schedule was
removed from the study after nine infusions at the investiga-
tor’s discretion, in order to increase the IVIG dose to 800 mg/
kg following exacerbation of the lung disease. All patients
enrolled in the study received at least nine infusions and pro-
vided data on infections by at least nine post-treatment diaries,
so all 51 patients were included in the FAS. One patient on the
4-week infusion schedule was excluded from the PP set for
major protocol violations, including missing two infusion
visits. The remaining patients (n = 50) comprised the PP anal-
ysis set.
There were no substantial differences in baseline character-
istics between the two treatment groups (Table 1). Briefly, the
mean age of the total population was 26.8 years (range 2–
65 years), 35% were female; 14% of all patients were of
Hispanic or Latino ethnicity. Twenty-one patients (41%) were
treated with 3-weekly infusions, and 30 patients (59%) with 4-
weekly infusions (Table 1). Of the 51 patients enrolled in the
study, 43 patients (84.3%) were diagnosed with CVID and
eight patients (15.7%) with XLA.
The mean duration of treatment was 360 days. Overall,
there were 740 infusions with an actual mean IgG dose of
417 g (range 104–1224 g) per patient, and a mean dose per
infusion of 485 mg/kg body weight. The mean duration of
each infusion was 2.2 h (range 1.4–4.3 h). Of the high-rate
infusions, 90.1% were administered at the maximum rate of
0.08 mL/kg/min.
Extension Study
The extension study enrolled 21 patients (eight children
[age ≥ 6 years to <12], three adolescents [≥12 to <16 years],
and ten adults [≥16 to ≤75]) from six US centers. All patients
completed the study. Thirty-eight percent of patients were
female and the mean age of the patient cohort was 23.8 years
(range 6–62 years). Hispanic or Latino ethnicity was reported
by 19% of patients. Most patients (76.2%) had CVID, while
the remainder had XLA.
The mean treatment duration was 107 days. Patients had a
total of 96 infusions. The actual mean dose of IgG per infusion
was 29.8 g or 542 mg/kg body weight. The mean duration of
each infusion was 1.5 h (range 1.2–2.0 h), and 85.2% of the
high rate infusions were administered at the maximum rate of
0.14 mL/kg/min.
Efficacy
Primary Endpoint
In the FAS, all SBIs reported were bacterial pneumonia, and
occurred in patients receiving 4-weekly infusions (Table 2).
The rate of SBIs per patient-year was less than 1.0 in all
treatment groups (Table 2). This result was confirmed in the
PP set, from which one patient with an SBI was excluded,
with a rate of SBI per patient-year for all patients of 0.061
(99% CI 0.0060–0.6246); of note, the excluded patient who
experienced an SBI missed two infusion visits and was late for
others and had low IgG levels during the study (≤500 mg/dL).
Secondary Endpoints
For both treatment schedules, trough levels of serum IgG were
almost constant throughout the study. Patients on a 4-week
infusion schedule had median IgG trough levels of 810–
870 mg/dL, while patients on a 3-week schedule had median
levels of 1100–1220 mg/dL. Over 75% of patients reported a
non-serious infection (Table 3). Infections occurring in >25%
of the total population included lower (LRTI) and upper respi-
ratory tract infections (URTIs) and infections of the gastrointes-
tinal tract. Patients in the 3-weekly group reported more URTIs
and ear infections than the 4-weekly group and fewer LRTIs
(Table 3). The rate of other infections per patient-year was 3.68
in the total patient group, with a higher rate for patients in the 3-
weekly schedule (4.19) than in the 4-weekly schedule (3.33).
The mean time to resolution of infection was 14.3 days for
SBIs and 18.4 days for other infections. The time to resolution
of non-serious infections was higher in the 4-weekly group vs
the 3-weekly group (21.4 vs 14.9 days), but high standard
deviations were seen in both groups (data not shown).
Antibiotics were used by 82.4% of patients during the
course of the study of which 86.0% were for therapeutic rea-
sons, while the rest were prophylactic use. The percentage of
patients using antibiotics was similar between treatment
groups (data not shown).
Overall, 49.0% of patients in the study had a total number
of 68 absences from work or school due to infections; the
percentage of patients taking absences and the number of ab-
sences were higher in the 3-weekly group (13 of 21 patients
[61.9%] and 37 absences) than in the 4-weekly group (12 of
30 patients [40.0%] and 31 absences). There were 183 days
missed fromwork/school during the study, and the mean num-
ber of days missed per patient-year was 3.64.
Only one patient treated at 4-week intervals was hospital-
ized due to infections (for bacterial pneumonia; total duration
of hospital stay 4 days; overall rate of days in hospital per
patient-year 0.080). Fourteen episodes of fever occurred in
11 patients (Table 4).
Safety
Main Study
Of the 51 patients in the safety set, 48 (94.1%) experienced ≥1
AE during the study. No AEs led to study withdrawal or death.
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Table 1 Baseline characteristics
and demographics of the main
study population
Parameter 3-weekly IVIG schedule
(n = 21)
4-weekly IVIG schedule
(n = 30)
Total
(n = 51)
Gender, n (%)
Female 7 (33.3) 11 (36.7) 18 (35.3)
Male 14 (66.7) 19 (63.3) 33 (64.7)
Age (years)
Mean ± SD 26.2 ± 21.2 27.2 ± 18.2 26.8 ± 19.3
Min, max 2, 65 5, 63 2, 65
Race, n (%)
White 21 (100.0) 30 (100.0) 51 (100.0)
Ethnicity, n (%)
Hispanic or Latino 3 (14.3) 4 (13.3) 7 (13.7)
Not Hispanic or
Latino
18 (85.7) 25 (83.3) 43 (84.3)
Not reported 0 (0.0) 1 (3.3) 1 (2.0)
Height (cm)
Mean ± SD 156.3 ± 25.3 156.7 ± 23.6 156.5 ± 24.1
Min, max 90, 191 108, 186 90, 191
Weight (kg)
Mean ± SD 59.7 ± 31.4 57.9 ± 23.0 58.7 ± 26.5
Min, max 13, 145 18, 100 13, 145
BMI (kg/m2)
Mean ± SD 22.8 ± 8.6 22.3 ± 4.6 22.5 ± 6.5
Min, max 15, 52 15, 32 15, 52
BMI body mass index, IVIG intravenous immunoglobulin, SD standard deviation
Fig. 1 Patient disposition
through the main study
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Serious (SAEs) and severe AEs occurred in five (9.8%) and
seven patients (13.7%), respectively. No children had SAE,
but four adults (15.4%) and one adolescent (8.3%) had seven
SAEs, all considered unrelated (gout, pneumonia, bronchiec-
tasis [twice], bronchospasm, septoplasty, and thrombocytope-
nia). Table 5 lists AEs experienced by >10% and related AEs
experienced by >3% of treated patients. Patients in the 4-
weekly group had a higher incidence of SAEs (13 vs 5%).
In contrast, more patients in the 3-weekly treatment group
had severe AEs than patients in the 4-weekly group (24 vs
7%).
During the course of this study, treatment-emergent
AEs that were classified by the investigator to be related
to the study medication occurred in 16 patients (31.4%);
six patients (28.6%) enrolled in the 3-weekly treatment
schedule and ten patients (33.3%) in the 4-weekly treat-
ment schedule. The age distribution was as follows:
42.3% of adults (62.5% 3-weekly; 33.3% 4-weekly
group), 25.0% of adolescents (12.5% 3-weekly; 50.0%
4-weekly group), and 15.4% of children (none 3-weekly;
25.0% 4-weekly group). The most common events in
adults were headache (26.9%), nausea (11.5%), and
vomiting, upper abdominal pain, and pyrexia (7.7% each),
while in adolescents, the most common were headache,
pyrexia, fatigue, and chills (8.3% each) and in children
abdominal pain (15.4%) and chills, headache, nausea,
and ear pain each in one case (7.7%). Only two patients
received premedication (3.9%) for three infusions (0.4%).
The maximum infusion rate of 0.08 mL/kg/min was used
in 90.1% of infusions after the seventh infusion. Study
medication-related (possible or probable) treatment-
emergent AEs occurred during 38 infusions (5.1%: 2.7%
in children, 2.2% in adolescent, and 7.8% in adult infu-
sions). Study medication-related headache was the most
abundant and noted in 22 infusions (3.0%). Most of these
(35/38) occurred within 72 h after end of infusion.
Table 3 Number of patients with
other infections, rate of other
infections per patient-year, main
study population
Other infections 3-weekly IVIG schedule
(n = 21)
4-weekly IVIG schedule
(n = 30)
Total
(n = 51)
Total no. of patients with other
infections, n (%)
18 (85.7) 21 (70.0) 39 (76.5)
Ear infections 5 (23.8) 4 (13.3) 9 (17.6)
Eye infections 1 (4.8) 2 (6.7) 3 (5.9)
GI tract infections 7 (33.3) 10 (33.3) 17 (33.3)
Genitourinary tract infections 2 (9.5) 3 (10.0) 5 (9.8)
URTI 14 (66.7) 14 (46.7) 28 (54.9)
LRTI 4 (19.0) 9 (30.0) 13 (25.5)
Skin infections 2 (9.5) 2 (6.7) 4 (7.8)
Infections not classified elsewhere 4 (19.0) 6 (20.0) 10 (19.6)
Total number of other infections, n 86 99 185
Number of patient-year exposure 20.5 29.7 50.2
Rate of other infections per
patient-year
4.19 3.33 3.68
One sided 95% CI, upper limit 6.89 5.17 5.12
CI confidence interval, GI gastrointestinal, IVIG intravenous immunoglobulin, LRTI lower respiratory tract
infection, URTI upper respiratory tract infection
Table 2 Serious bacterial
infections (SBIs) per patient-year
in the main study population
SBI 3-weekly IVIG schedule
(n = 21)
4-weekly IVIG schedule
(n = 30)
Total
(n = 51)
Total no. of SBI, n 0 4 4
Bacterial pneumonia 0 4 4
Total no. of patients with SBI,
n (%)
0 (0.0) 2 (6.7) 2 (3.9)
Bacterial pneumonia 0 (0.0) 2 (6.7) 2 (3.9)
Number of patient years
exposure
20.5 29.7 50.2
Rate of SBI per patient-year na 0.135 0.080
One sided 99%CI, upper limit na 0.849 0.503
CI confidence interval, IVIG intravenous immunoglobulin, na not applicable, no. number
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Only 13 infusions had clinically significant abnormal
values in hematology parameters or urinalysis, and none was
present in three or more infusions. There were no abnormali-
ties in direct Coombs test, biochemical assessments, viral
markers, vital signs, and physical examinations. Three
patients had hematological AEs; one patient had leukopenia
(no treatment was required), one had thrombocytopenia, and
one had anemia (both resolved due to effective treatment). No
change to the study medication administration schedule was
required in these patients.
Extension Study
Of the 21 patients in the safety set, 17 (81.0%) experienced at
least one AE during the study which were generally mild to
moderate in intensity with only one patient having severe AEs
(4.8%). No AEs led to study withdrawal or death. No SAEs
were reported. Table 6 lists AEs experienced by at least two
(9.5%) and the related AEs experienced by >3% of treated
patients. There was a higher overall incidence of AEs in pa-
tients receiving the 3-week treatment schedule than the 4-
week schedule (91.7 vs 66.7%), as well as a higher incidence
of related AEs (25.0 vs 11.1%) and severe AEs (8.3 vs 0%).
AEs were considered treatment-related in four patients
(19.0%); two children had a total of three related AEs (abdom-
inal pain, headache, and vascular procedure complication each
12.5%) and two adults had a total of six related AEs (nausea
Table 5 Display of all adverse
events (AEs; frequency >10% of
the 51 total patients) and study
medication-related AEs (frequen-
cy >3%) by MedDRA System
Organ Class and Preferred Term
in the main study population
Adverse event All AEs, n (%) Related AEs, n (%)
Infections and infestations 40 (78.4) 0 (0.0)
Upper respiratory tract infection 15 (29.4)
Nasopharyngitis 13 (25.5)
Sinusitis 13 (25.5)
Bronchitis 8 (15.7)
Gastroenteritis 8 (15.7)
Otitis media 7 (13.7)
Influenza 6 (11.8)
Pharyngitis 6 (11.8)
Gastrointestinal disorders 27 (52.9) 7 (13.7)
Abdominal pain 11 (21.6) 5 (9.8)
Nausea 7 (13.7) 4 (7.8)
Vomiting 7 (13.7) 2 (3.9)
General disorders and administration site conditions 27 (52.9) 8 (15.7)
Pyrexia 11 (21.6) 3 (5.9)
Fatigue 10 (19.6) 2 (3.9)
Chills 2 (3.9)
Nervous system disorders 20 (39.2) 9 (17.6)
Headache 14 (27.5) 9 (17.6)
Respiratory, thoracic and mediastinal disorders 20 (39.2) 1 (2.0)
Cough 7 (13.7) 1 (2.0)
Musculoskeletal and connective tissue disorders 14 (27.5) 1 (2.0)
Pain in extremity 6 (11.8)
Injury, poisoning and procedural complication 9 (17.6) 0 (0.0)
Skin and subcutaneous tissue disorders 9 (17.6) 0 (0.0)
Metabolism and nutrition disorders 6 (11.8) 0 (0.0)
Table 4 Total number of episodes of fever in the main study population
Episodes of
fevera
Children
≥2 years,
<12 years
(n = 13)
Adolescents
≥12 years,
<16 years
(n = 12)
Adults
≥16 years,
≤75 years
(n = 26)
Total
(n = 51)
No. of patients
with fever,
n (%)
5 (38.5) 1 (8.3) 5 (19.2) 11
(21.-
6)
Total no. of
episodes of
fever, n
6 2 6 14
Rate of
episodes of
fever per
patient-year
0.463 0.174 0.233 0.279
no. number
a As determined by the investigator
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20%; arthralgia, musculoskeletal pain, headache, and chest
pain, each 10%).
No patients received premedication. The maximum infu-
sion rate of 0.14 mL/kg/min was used in 19/21 patients. Study
medication-related (possible or probable) treatment-emergent
AEs were observed with six infusions (6.3%), 8.3% in chil-
dren, none in adolescent, and 6.7% in adult infusions.
Headache was the most abundant event during the extension
study and noted in three infusions (3.1%).
There were no clinically significant changes in laboratory
parameters and no prominent results from vital signs or phys-
ical examination during the extension period.
Discussion
Both the FDA and EMA recommend that a finding of a seri-
ous infection rate per patient-year of <1.0 is adequate evidence
of efficacy of IVIG as substitution therapy [8, 9]. The current
study meets this requirement, with a rate of SBI as low as 0.08
overall, confirming the efficacy of panzyga® in preventing the
occurrence of SBIs in patients with PID. This low rate of SBIs
as well as the low rate of other infections (3.7 per patient/year)
further confirms that the dosing and corresponding trough
levels observed in this study were adequate. The average dose
calculated by body weight at each infusion was 485 mg/kg
body weight, which is in line with doses recommended in the
core summary of product characteristics. Serum IgG trough
levels were nearly constant for both treatment schedules dur-
ing the course of the study and exceeded the trough level of
600 mg/dL recommended by EMA [10].
The results from the present study are consistent with other
clinical trials investigating the efficacy of IVIG in patients
with antibody-deficient PID. A study of 80 adults and children
with CVID or XLA treated with Privigen® 10% at a dose of
200–888 mg/kg every 3 or 4 weeks for 12 months had an
annual SBI rate of 0.08 (upper one-sided 97.5% CI 0.182),
while the annual rate of all infections was 3.55 [11], similar
rates to those seen in the present study. The average annual
rate of missed school or work days was 7.94 days/patient [11],
a higher rate than what was seen with panzyga®. In another
study of 22 patients with PID receiving 300–450 mg/kg
Kiovig 10% every 3 weeks, no episodes of severe infection
were reported, and the median monthly rate of mild or mod-
erate infection episodes was 0.48. The rate of days off work/
school per month ranged from 0 to 1.58 in the observational
period [12].
Other clinical trials include a 46-patient study of octagam®
5% IVIG (400 or 600 mg/kg every 28 days or 300–450 mg/kg
every 21 days) for 12months, in which the estimated infection
rate was 0.1 SBIs/patient/year (98% CI 0.033–0.279) and
mean number of days of work or school missed was 5 during
the course of the study; both outcomes were similar to those in
the present study [13]. A study with Flebogamma® 10% DIF
Table 6 Display of all adverse
events (AEs) and study
medication-related AEs (frequen-
cy at least two [all AEs] or one
[related AEs] of the total 21 pa-
tients) by MedDRA System
Organ Class and Preferred Term
in the extension study population
Adverse event All AEs, n (%) Related AEs, n (%)
Infections and infestations 9 (42.9) 0 (0.0)
Sinusitis 4 (19.0)
Nasopharyngitis 2 (9.5)
Gastrointestinal disorders 7 (33.3) 3 (14.3)
Nausea 3 (14.3) 2 (9.5)
Vomiting 3 (14.3) 0 (0.0)
Abdominal pain 2 (9.5) 1 (4.8)
Diarrhea 2 (9.5) 0 (0.0)
General disorders and administration site conditions 1 (4.8)
Chest pain 4 (19.0) 1 (4.8)
Pyrexia 2 (9.5) 0 (0.0)
Nervous system disorders 2 (9.5) 2 (9.5)
Headache 2 (9.5) 2 (9.5)
Respiratory, thoracic and mediastinal disorders 5 (23.8) 0 (0.0)
Musculoskeletal and connective tissue disorders 2 (9.5) 2 (9.5)
Arthralgia <2 1 (4.8)
Musculoskeletal pain <2 1 (4.8)
Injury, poisoning and procedural complication 6 (28.6) 1 (4.8)
Contusion 2 (9.5) 0 (0.0)
Vascular procedure complication <2 1 (4.8)
Skin and subcutaneous tissue disorders 2 (9.5) 0 (0.0)
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infused at a dose of 300–600 mg/kg every 3 or 4 weeks for
12 months in 46 PID patients reported that the overall rate of
acute SBIs/patient/year was 0.025 (98% CI 0.001–0.133) and
the overall mean rate of all infections was 2.2/patient/year,
with 43% patients reporting missing at least 1 day of
work/school/usual activities, with the mean number of days
lost being 3.0 [14]. A 12-month study of Bivigam® 300–
800 mg/kg infused every 3 or 4 weeks into 63 patients with
PID demonstrated a SBI rate of 0.035/patient/year, and a gen-
eral infection rate of 2.6/patient/year. Days off work or school
were 2.28/patient/year [15], results again similar to our study.
In the present study, the proportion of patients who expe-
rienced infections other than SBIs was greater and the rate of
URTIs was higher in the 3-weekly group than in the 4-weekly
group. This could have been a chance occurrence that may
have taken place in any random grouping of patients, as the
patients continued with their treatment schedule and dose that
they had received before enrolment into this study.
Alternatively, it is possible that patients who were placed on
a 3-weekly schedule for IVIG treatment were likely to have a
more compromised immune system and, therefore, be at
greater risk of developing such infections.
The majority of AEs were assessed as mild; none led to
study withdrawal or death. None of the patients in the study
exhibited signs of hemolysis. As expected, the most frequent
related AE observed was headache. The tolerability and safety
profile was excellent at high infusion rates. Indeed, panzyga®
could be safely administered at infusion speeds that were
equal [16] or considerably higher than used in most clinical
trials treating antibody-deficient patients with IVIG, exceed-
ing the maximum approved rates for most IVIG preparations
[11, 17, 18]. Most patients (>90%) in the extension study
tolerated the highest infusion speed of 0.14 mL/kg/min
(840 mg/kg/h), without any associated increase in rates of
AEs. In fact, there was a decrease in the related AE rate from
31.4% in the main study to 19.0% in the extension study.
The strengths of the study include its multicenter, interna-
tional design, and the wide age range of the patients, which
makes the results applicable to an extended population. The
high proportion of patients (96%) completing the study with-
out any major protocol violation is an additional strength.
Limitations of the study include the lack of a comparator
group and a lack of blinding, although it should be noted that
this study was designed in accordance with the study design
recommendations of the FDA and the EMA for studies of
IVIG in the treatment of PID [8, 9].
Conclusion
These results demonstrate that treatment with panzyga® is
highly effective in PID patients with predominant antibody
deficiency and has excellent tolerability; patients exhibited a
very low level of SBIs and a low rate of related AEs, even
when infusion rates were increased up to 0.14 mL/kg/min.
Acknowledgements The authors would like to thank Sheridan
Henness, PhD, of Springer Healthcare Communications for the medical
writing assistance; this assistance was funded by Octapharma AG. The
authors would also like to thank Dr. Stefan Wietek and Dr. Ursula
Konheiser from Octapharma Vienna, Austria and Lachen, Switzerland,
respectively, for their assistance with preparation of the manuscript.
Thanks also go to the patients who took part in this study, and the mem-
bers of the data monitoring committee: Prof. Volker Wahn, Prof. Deborah
Kado, and Prof. Luc Mouthon.
Authorship Contributions Dr. Borte, Dr. Melamed, Dr. Pulka, Dr.
Knutsen, Dr. Moy, Dr. Ochs, Dr. RH Kobayashi, Dr. AL Kobayashi,
Dr. Gupta, Dr. Strach, Dr. Smits, and Dr. Pituch-Noworolska recruited
patients for the trial and were responsible for the supervision of the trial at
their respective sites; they also participated in the editing of the manu-
script. Barbara Pyringer was involved in the planning, management, and
reporting of the study, as well as in the preparation of the manuscript.
Compliance with Ethical Standards
Conflict of Interest M Borte’s institution has received research grant
support from CSL Behring, Octapharma, and Baxalta, and he has partic-
ipated in advisory boards for CSL Behring and Octapharma. IRMelamed
has received research grant support from CSL Behring, Octapharma,
Baxalta, and Bio Products Laboratories. B. Pyringer is an employee of
Octapharma, Vienna, Austria. AP Knutsen has acted as a consultant for
Baxalta, CSL, and Octapharma. HD Ochs has acted as consultant for
Baxalta, CSL Behring, and Octapharma. RH Kobayashi has acted as a
consultant for Baxalta, CSL, ADMA, and Octapharma. AL Kobayashi
received grant support from Baxalta and Octapharma. JN Moy has re-
ceived fees as a consultant for Grifols, Prometic, Octapharma,
MacroCure, and Baxalta. G Pulka, S Gupta, M Strach, W Smits, and A
Pituch-Noworolska have no conflicts of interest to declare. Open Access
for this Article was funded by Octapharma.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary
immunodeficiencies: a rapidly evolving story. J Allergy Clin
Immunol. 2013;131(2):314–23. doi:10.1016/j.jaci.2012.11.051.
2. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley
ME, et al. Primary immunodeficiency diseases: an update on the
classification from the International Union of Immunological
Societies Expert Committee for Primary Immunodeficiency 2015.
J Clin Immunol. 2015;35(8):696–726. doi:10.1007/s10875-015-
0201-1.
3. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of
life, immunoglobulin G levels, and infection rates in patients with
primary immunodeficiency diseases during self-treatment with sub-
cutaneous immunoglobulin G. South Med J. 2010;103(9):856–63.
doi:10.1097/SMJ.0b013e3181eba6ea.
J Clin Immunol (2017) 37:603–612 611
4. Kersey JH, Spector BD, Good RA. Primary immunodeficiency
diseases and cancer: the immunodeficiency-cancer registry. Int J
Cancer. 1973;12(2):333–47.
5. Westerberg LS, Klein C, Snapper SB. Breakdown of T cell toler-
ance and autoimmunity in primary immunodeficiency—lessons
learned from monogenic disorders in mice and men. Curr Opin
Immunol. 2008;20(6):646–54. doi:10.1016/j.coi.2008.10.004.
6. Cunningham-Rundles C. Key aspects for successful immunoglob-
ulin therapy of primary immunodeficiencies. Clin Exp Immunol.
2011;164(Suppl 2):16–9. doi:10.1111/j.1365-2249.2011.04390.x.
7. Yong PL, Boyle J, BallowM, Boyle M, Berger M, Bleesing J, et al.
Use of intravenous immunoglobulin and adjunctive therapies in the
treatment of primary immunodeficiencies: a working group report
of and study by the Primary Immunodeficiency Committee of the
American Academy of Allergy Asthma and Immunology. Clin
Immunol. 2010;135(2):255–63. doi:10.1016/j.clim.2009.10.003.
8. US Food and Drug Administration. Guidance for industry: safety,
efficacy, and pharmacokinetic studies to support marketing of im-
mune globulin intravenous (human) as replacement therapy for pri-
mary humoral immunodeficiency. 2008. http://www.fda.gov/
d o w n l o a d s / B i o l o g i c s B l o o d V a c c i n e s /
GuidanceComplianceRegulatoryInformation/Guidances/Blood/
ucm078526.pdf. Accessed 27 February 2015.
9. European Medicines Agency. Guideline on the clinical investiga-
tion of human normal immunoglobulin for intravenous administra-
tion (IVIg). EMA/CHMP/BPWP/94033/2007 rev. 2. 2010. http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2009/10/WC500004766.pdf. Accessed 20 December
2016.
10. European Medicines Agency. Guideline on core SmPC for human
normal immunoglobulin for intravenous administration (IVIg).
EMA/CHMP/BPWP/94038/2007 Rev. 5. 2016. http://www.ema.
europa.eu/docs/en_GB/document_library/Scientific_guideline/
2016/12/WC500219036.pdf. Accessed 13 January 2017.
11. Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M,
Vermylen C, et al. Safety and efficacy of Privigen, a novel 10%
liquid immunoglobulin preparation for intravenous use, in patients
with primary immunodeficiencies. J Clin Immunol. 2009;29(1):
137–44. doi:10.1007/s10875-008-9231-2.
12. Bjorkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J,
Lumio JT, et al. Prospective open-label study of pharmacokinetics,
efficacy and safety of a new 10% liquid intravenous immunoglob-
ulin in patients with hypo- or agammaglobulinemia. Vox Sang.
2006;90(4):286–93. doi:10.1111/j.1423-0410.2006.00764.x.
13. Ochs HD, Pinciaro PJ. Octagam 5%, an intravenous IgG product, is
efficacious and well tolerated in subjects with primary immunode-
ficiency diseases. J Clin Immunol. 2004;24(3):309–14. doi:10.
1023/B:JOCI.0000025453.23817.3f.
14. Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J,
et al. Efficacy, pharmacokinetics, safety, and tolerability of
Flebogamma 10% DIF, a high-purity human intravenous immuno-
globulin, in primary immunodeficiency. J Clin Immunol.
2010;30(2):321–9. doi:10.1007/s10875-009-9348-y.
15. WassermanRL, Church JA, SteinM,Moy J,WhiteM, Strausbaugh
S, et al. Safety, efficacy and pharmacokinetics of a new 10% liquid
intravenous immunoglobulin (IVIG) in patients with primary im-
munodeficiency. J Clin Immunol. 2012;32(4):663–9. doi:10.1007/
s10875-012-9656-5.
16. Gelfand EW, Hanna K. Safety and tolerability of increased rate of
infusion of intravenous immunoglobulin G, 10% in antibody-
deficient patients. J Clin Immunol. 2006;26(3):284–90. doi:10.
1007/s10875-006-9014-6.
17. Ochs HD, Buckley RH, Pirofsky B, Fischer SH, Rousell RH,
Anderson CJ, et al. Safety and patient acceptability of intravenous
immune globulin in 10% maltose. Lancet. 1980;2(8205):1158–9.
18. Ochs HD, Lee ML, Fischer SH, Kingdon HS, Wedgwood RJ.
Efficacy of a new intravenous immunoglobulin preparation in pri-
mary immunodeficient patients. Clin Ther. 1987;9(5):512–22.
612 J Clin Immunol (2017) 37:603–612
